Current guidelines for malaria treatment in Somalia: evidence-based recommendations
DOI:
https://doi.org/10.36368/shaj.v1i1.249Keywords:
Somalia, malaria, artemisinin-based combination therapy, treatment guidelinesAbstract
Case management – rapid diagnosis and prompt administration of artemisinin-based combination therapy (ACT) – is a fundamental pillar of recommended malaria interventions in Somalia. Unfortunately, the emergence and spread of drug resistant falciparum parasites continues to pose a considerable threat to effective case management.
With technical and financial support from WHO, the efficacy of recommended ACTs has been regularly monitored in sentinel sites since 2003. These studies provided evidence that supported the adoption of artesunate-sulfadoxine/pyrimethamine as first-line treatment in 2005 and artemether-lumefantrine as second-line treatment in 2011. Efficacy studies conducted between 2011 and 2015 showed high artesunate-sulfadoxine/pyrimethamine treatment failure rates of 12.3% - 22.2%, above the threshold (10%) for a change of treatment policy as recommended by WHO. This was also associated with high prevalence of quadruple and quintuple mutations in the dihydrofolate reductase (Pfdhfr) and dihydropteroate synthase (Pfdhps) genes, which are associated with sulfadoxine/pyrimethamine resistance.
Based on these findings, national malaria treatment guidelines were updated in 2016, with artesunate-sulfadoxine/pyrimethamine replaced by artemether-lumefantrine as first-line treatment and dihydroartemisinin-piperaquine recommended as second-line treatment. Subsequent efficacy studies in 2016 and 2017 confirmed that both the current first- and second-line treatments remain highly efficacious (cure rate above 97%). Technical and financial support from WHO has been instrumental in generating evidence that informs malaria treatment policy and should therefore continue to ensure that effective treatments are available to malaria patients in the country.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2021 Marian Warsame, Ali Abdulrahman Osman, Abdikarim Hussein Hassan, Abdi Abdulle, Abdikarim Muse, Abdilahi Mohamed Hassan, Mohamed Abdullahi Ali, Fahmi Essa Yusuf, Jamal Hefzullah Amran
This work is licensed under a Creative Commons Attribution 4.0 International License.
This is an open access journal, which means that all content is freely available without charge to the user or his/her institution. Users are allowed to read, download, copy, distribute, print, search, or link to the full texts of the articles featured in the journal without asking prior permission from the publisher or the author. This is in accordance with definition of open access as formulated by the Budapest Open Access Initiative (BOAI). All authors who publish in this journal agree to the following terms:
- Authors retain copyright and grant the SHAJ the right of first publication. The work is licensed under Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which allows others to share and distribute the work as long as it is attributed to the author and its initial publication in the SHAJ is acknowledged.
- Authors are encouraged to distribute the work themselves with information on its initial publication in the SHAJ, e.g. upload it to open repositories linked to their personal website or institutional affiliation, or publish it in a book.
The SHAJ is permitted non-exclusive distribution of the work, with attribution to the author, e.g. in a print book themed anthology.
